�鶹ֱ��

�鶹ֱ�� & Lardner LLP today published its fourth annual Health Care & Life Sciences Top Trends report exploring significant business and legal issues arising from the rapid regulatory changes and technology advancements that are transforming this space.

Multiple interconnected factors are driving developments and spurring companies across the health care and life sciences sectors to adjust focus and adapt to the shifting terrain. As the second Trump administration ushers in change at all levels of the federal government, health care and life sciences companies are emphasizing preparation for that transformation and its accompanying uncertainty.

New leadership in Washington comes with evolving enforcement priorities on issues like the False Claims Act (FCA), making health care litigation a key space to watch. Incoming changes at the Centers of Medicare & Medicaid Services (CMS) raise questions about the Medicare Advantage program’s future, and the fallout from the U.S. Supreme Court’s Chevron overturn continues to fuel developments in health care litigation.

Health care and life sciences companies are also keeping a close eye on M&A oversight. While the new administration’s approach on competition issues has yet to take shape, a flurry of legislative activity at the state level has introduced additional regulatory scrutiny on health care transactions to address competition, quality, access, and cost of health care.

Artificial intelligence (AI) also remains at the forefront of business disruption. With the legal and regulatory frameworks covering AI still in their infancy, health care and life sciences companies need to balance the competitive advantages AI implementation can deliver against an intricate web of requirements, challenges, and risks.

“The modern health care and life sciences environment requires businesses to continually deliver better patient care more efficiently, all while staying closely attuned to government decision making, market forces, and the relentless pace of technological advancement,” said Susan Pravda, chair of �鶹ֱ��’s Health Care & Life Sciences Sector.

�鶹ֱ��’s 2025 Health Care & Life Sciences Top Trends publication unravels this complex ecosystem, exploring these topics and more to help companies maximize opportunities and steer clear of challenges.

Articles include:

• Government Enforcement and Health Care Litigation Under the Trump Administration’s Health Care Policies
• Medicare Payment Model Trends and Economic Drivers: Awaiting Direction from Trump Administration
• Private Equity and Health Care: Navigating Health Care Transaction Review Laws in 2025
• Health Care Data Deals & Transactions: Maximizing Value and Navigating Legal Risks
• Increased Scrutiny, New Regulations, and Therapy Changes: Five Trends Revolutionizing Behavioral Health
• Post-Chevron Deference: A New Era for Legal Challenges to Health Care Regulations
• Top Trends in Antitrust Enforcement in Health Care: Private Equity, Pharmacy Benefit Managers (PBMs), Labor Protections, and more
• What’s Next for Telehealth and Digital Health Policy? Five Trends to Watch in 2025
• Artificial Intelligence (AI) Deployment Trends in Health Care and Life Sciences: How to Define and Execute Resilient Governance Frameworks
• Artificial Intelligence (AI) Patent Strategies for Medical Devices: IP Playbook for Emerging MedTech Companies
• Copyright Law Considerations for Artificial Intelligence (AI) in Pharmaceutical & Biopharmaceutical Industries
• Artificial Intelligence (AI)/Machine Learning (ML) in Medical Devices: FDA Continues to Develop its Regulatory Approach
• The Unique Role Artificial Intelligence (AI) Can Play in Pharmaceutical Clinical Trial Diversity

��DZ����’s��Health Care & Life Sciences Sector is comprised of more than 200 attorneys with decades of collective in-house experience at health care providers and vendors, pharmaceutical and biotechnology firms, and key state and federal government agencies. �鶹ֱ�� is primed to strategically advise health care and life sciences companies through every step of their journey and all stages of their lifecycle. With deep regulatory experience coupled with a national transaction backbone, attorneys provide forward-looking, practical solutions to clients’ most pressing business challenges.

Access the full report here.

About �鶹ֱ�� & Lardner LLP

�鶹ֱ�� & Lardner LLP is a preeminent law firm that stands at the nexus of the Energy, Health Care & Life Sciences, Innovative Technology, and Manufacturing �鶹ֱ��. We look beyond the law to focus on the constantly evolving demands facing our clients and act as trusted business advisors to deliver creative, practical, and effective solutions. Our 1,100 lawyers across 26 offices worldwide partner on the full range of engagements from corporate counsel to intellectual property work and litigation support, providing our clients with a one-team solution to all their needs. For nearly two centuries, �鶹ֱ�� has maintained its commitment to the highest level of innovative legal services and to the stewardship of our people, firm, clients, and the communities we serve.